Australia markets open in 1 hour 55 minutes

ImmunityBio, Inc. (IBRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.65-0.10 (-1.29%)
At close: 04:00PM EDT
7.68 +0.03 (+0.39%)
After hours: 07:58PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 5.29B
Enterprise value 5.85B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)14.43k
Price/book (mrq)N/A
Enterprise value/revenue 19.38k
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) -0.23
52-week change 3174.19%
S&P500 52-week change 326.49%
52-week high 310.53
52-week low 31.25
50-day moving average 36.32
200-day moving average 33.89

Share statistics

Avg vol (3-month) 37.45M
Avg vol (10-day) 36.17M
Shares outstanding 5691.57M
Implied shares outstanding 6691.57M
Float 8160.49M
% held by insiders 177.59%
% held by institutions 19.81%
Shares short (30 Apr 2024) 455.14M
Short ratio (30 Apr 2024) 45.19
Short % of float (30 Apr 2024) 438.87%
Short % of shares outstanding (30 Apr 2024) 48.14%
Shares short (prior month 28 Mar 2024) 454.77M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-237,989.99%

Management effectiveness

Return on assets (ttm)-57.95%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)302k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)-88.90%
Gross profit (ttm)N/A
EBITDA -326.59M
Net income avi to common (ttm)-600.96M
Diluted EPS (ttm)-1.08
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)170.5M
Total cash per share (mrq)0.25
Total debt (mrq)895.42M
Total debt/equity (mrq)N/A
Current ratio (mrq)3.64
Book value per share (mrq)-1.02

Cash flow statement

Operating cash flow (ttm)-389.43M
Levered free cash flow (ttm)-269.38M